Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of sodium dichloroacetate as single agent or in combination with cisplatin in normal and human cervical cancer cell lines

Alejandro Zugasti¹, Ana L Rivera¹, Sonia Y Silva², Miguel A Alfaro¹, Crystel A Sierra¹ ,

¹Laboratory of Immunology and Toxicology; ²Department of Science in Bioactive Compounds, Faculty of Chemistry, Autonomous University of Coahuila. Saltillo, Coahuila, Mexico.

For correspondence:- Crystel Sierra Email: crycrystelsierrarivera@uadec.edu.mx Tel:+5218444390511

Accepted: 26 February 2020 Published: 31 March 2020

Citation: Zugasti A, Rivera AL, Silva SY, Alfaro MA, Sierra CA, Effect of sodium dichloroacetate as single agent or in combination with cisplatin in normal and human cervical cancer cell lines. Trop J Pharm Res 2020; 19(3):467-474 doi: 10.4314/tjpr.v19i3.2

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the synergistic cytotoxicity of sodium dichloroacetate (DCA) in combination with cisplatin (CIS) against human cervical cancer cell lines.

Methods: Cervical cancer SiHa and HeLa cells and normal cells (Hek-293, Vero, peripheral blood mononuclear and human erythrocytes) were treated in vitro with DCA and CIS individually or their combination. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method while hemolytic activity was evaluated from the released hemoglobin. Half-maximal inhibitory concentration (IC50) of DCA or CIS was obtained.

Results: The combination of DCA + CIS decreased the cell viability of SiHa, Hek-293, Vero, and PBMC cells, but not of Hela cells (p < 0.05). Furthermore, the individual treatments alone or in combination did not cause significant hemolysis (p < 0.05).

Conclusion: The combination of DCA + CIS increases the damage caused by CIS alone on SiHa cells. It also decreases the cell viability of Hek-293 and Vero without affecting peripheral blood mononuclear and human erythrocyte integrity. The results suggest that the combination of DCA and CIS can induce synergistic antitumor effect in different types of cancer cell lines. However, further studies are required to determine the biological effects of the combination of DCA and CIS in vivo.

Keywords: Cervical cancer, Sodium dichloroacetate, Cisplatin, Viability, Hemolysis